Conflicts of interest for patient-advocacy organizations

New England Journal of Medicine

Volumn 376, Issue 9, 2017, Pages 880-885

  McCoy, Matthew S ^a   Carniol, Michael ^b   Chockley, Katherine ^a   Urwin, John W ^a   Emanuel, Ezekiel J ^a   Schmidt, Harald ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOSTATISTICS; CLINICAL PRACTICE; CONFLICT OF INTEREST; DIAGNOSTIC TEST; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH PROMOTION; HUMAN; MEDICAL RESEARCH; NON PROFIT ORGANIZATION; PATIENT ADVOCACY; PATIENT CARE; UNITED STATES; WELLBEING; ECONOMICS; ETHICS; PRIVATE SECTOR; TAX;

CONFLICT OF INTEREST; FINANCIAL SUPPORT; HUMANS; ORGANIZATIONS, NONPROFIT; PATIENT ADVOCACY; PRIVATE SECTOR; TAXES; UNITED STATES;

EID: 85014795791     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr1610625     Document Type: Article

References (21)

1. National Health Council. Membership directory. 2016 (http://www .nationalhealthcouncil .org/about-nhc/membership-directory).
2. Rose SL. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness. J Law Med Ethics 2013; 41: 680-7.
3. Rothman SM, Raveis VH, Friedman A, Rothman DJ. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices. Am J Public Health 2011; 101: 602-9.
4. Dresser R. When science offers salvation: patient advocacy and research ethics. New York: Oxford University Press, 2001.
5. Davis C, Abraham J. Unhealthy pharmaceutical regulation: innovation, politics and promissory science. Basingstoke, United Kingdom: Palgrave Macmillan, 2013.
6. O'Donnell J. Patient groups funded by drugmakers are largely mum on high drug prices. USA Today. January 21, 2016 (http://www .usatoday .com/story/news/nation/2016/01/21/patient-groups-drug-makers-high-drug-prices/79001722/).
7. Rosenberg M. Bone associations funded by Big Pharma push questionable drugs on women. June 13, 2016 (http://www .theepoch times .com/n3/2089469-bone-associations-funded-by-big-pharma-push-questionable-drugs-on-women/).
8. Meyer B. Fibromyalgia: drugmakers' push is boosting 'murky' ailment, influencing patients, doctors. February 8, 2009 (http://www .cleveland .com/nation/index .ssf/2009/02/fibromyalgia-drugmakers-push-i .html).
9. Claypool R. Patients' groups and big pharma. Washington, DC: Public Citizen, August 4, 2016.
10. Weisman R. Biotechs leverage patient groups in drug development. Boston Globe. September 29, 2016.
11. Thomas K. Furor over drug prices puts patient advocacy groups in bind. New York Times. September 27, 2016.
12. Emanuel EJ, Steiner D. Institutional conflict of interest. N Engl J Med 1995; 332: 262-7.
13. Lo B, Field MJ, eds. Conflict of interest in medical research, education, and practice. Washington, DC: National Academies Press, 2009 (http://nationalacademies .org/hmd/reports/2009/conflict-of-interest-in-medical-research-education-and-practice .aspx).
14. Marshall J, Aldhous P. Patient groups special: swallowing the best advice? New Scientist. October 25, 2006 (https://www .newscientist .com/article/mg19225755-100-patient-groups-special-swallowing-the-best-advice/).
15. Jacobson MF. Lifting the veil of secrecy: corporate support for health and environmental professional associations, charities, and industry front groups. Washington, DC: Center for Science in the Public Interest, 2003 (https://cspinet .org/resource/lifting-veil-secrecy).
16. Ethics and disclosure: how health nonprofits handle contributions from medical companies. Chronicle of Philanthropy. September 6, 2010 (https://philanthropy .com/article/How-Health-Nonprofits-Handle/160015/).
17. Ball DE, Tisocki K, Herxheimer A. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey. BMC Public Health 2006; 6: 201.
18. Abola MV, Prasad V. Industry funding of cancer patient advocacy organizations. Mayo Clin Proc 2016; 91: 1668-70.
19. Pham-Kanter G, Mello MM, Lehmann LS, Campbell EG, Carpenter DC. Public awareness of and contact with physicians who receive industry payments: a national survey. J Gen Intern Med (in press).
20. Kreis J, Schmidt H. Public engagement in health technology assessment and coverage decisions: a study of experiences in France, Germany, and the United Kingdom. J Health Polit Policy Law 2013; 38: 89-122.
21. McCoy MS, Emanuel EJ. Health policy: addressing conflicts of interest of public speakers at advisory committee meetings. Nat Rev Clin Oncol 2016; 13: 267-8.